Amgen Inc. (AMGN) Holdings Boosted by Honkamp Krueger Financial Services Inc.
Honkamp Krueger Financial Services Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,390 shares of the medical research company’s stock after purchasing an additional 63 shares during the quarter. Honkamp Krueger Financial Services Inc.’s holdings in Amgen were worth $928,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Amgen in the 1st quarter valued at about $110,402,000. Swiss National Bank increased its position in Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after purchasing an additional 551,600 shares during the period. Bank of Nova Scotia increased its position in Amgen by 414.4% during the 1st quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after purchasing an additional 484,868 shares during the period. AQR Capital Management LLC increased its position in Amgen by 37.4% during the 1st quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock worth $236,775,000 after purchasing an additional 392,538 shares during the period. Finally, Morningstar Investment Services LLC increased its position in Amgen by 283.8% during the 1st quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after purchasing an additional 367,894 shares during the period. Institutional investors own 78.10% of the company’s stock.
AMGN has been the topic of a number of research reports. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a report on Friday, June 30th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $177.00 price target on Amgen and gave the stock a “hold” rating in a report on Friday, July 14th. Morgan Stanley increased their price target on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. Finally, Deutsche Bank AG restated a “hold” rating and set a $174.00 price objective (up from $172.00) on shares of Amgen in a report on Wednesday, July 26th. Ten investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $189.99.
WARNING: “Amgen Inc. (AMGN) Holdings Boosted by Honkamp Krueger Financial Services Inc.” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/amgen-inc-amgn-holdings-boosted-by-honkamp-krueger-financial-services-inc/1614216.html.
Amgen Inc. (NASDAQ:AMGN) opened at 185.82 on Friday. The company has a 50 day moving average of $181.33 and a 200 day moving average of $170.23. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10. The company has a market capitalization of $135.59 billion, a PE ratio of 16.93 and a beta of 1.36. Amgen also was the target of unusually large options trading on Thursday. Stock traders purchased 9,350 put options on the company. This is an increase of approximately 239% compared to the typical daily volume of 2,758 put options.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.84 EPS. On average, equities research analysts forecast that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.